Baird Medical Showcases MWA Platforms at NASIT 2026 to Accelerate U.S. Expansion
Baird Medical showcased its proprietary Microwave Ablation platforms to key opinion leaders and emerging physicians at the North American Society for Interventional Thyroidology (NASIT) 2026 in Portland, driving targeted discussions on clinical applications. The engagement advances its U.S. expansion strategy for minimally invasive thyroid treatments across leading medical centers.
1. NASIT 2026 Showcase
At NASIT 2026 in Portland, Oregon, Baird Medical showcased its proprietary Microwave Ablation (MWA) platforms during the thermal ablation workshop and at its dedicated exhibit, attracting significant interest from key opinion leaders and emerging physicians focused on minimally invasive thyroid treatments.
2. Engagements with Key Opinion Leaders
Company leadership held targeted discussions with established KOLs and new specialists, exchanging insights on integrating MWA into clinical workflows and demonstrating the precision and non-surgical benefits of its technology.
3. Accelerating U.S. Expansion
The engagement aligns with the company’s U.S. expansion strategy, aiming to accelerate adoption of precision, non-surgical thyroid interventions and expand patient access across leading medical centers.
4. Global Market Footprint
As an FDA 510(k)-certified device provider, Baird Medical’s MWA solutions are used in over 30 U.S. hospitals and lead the thyroid microwave ablation market in China, with commercial presence growing in more than 20 countries worldwide.